Condition:   Eyelid Diseases
Intervention:   Device: LT2420
Sponsor:   Laboratoires Thea
Not yet recruiting - verified March 2010

Condition:   Leg Ulcer
Interventions:   Device: AQUACEL® Ag;   Device: Urgotul® Silver
Sponsor:   ConvaTec Inc.
Recruiting - verified March 2010

Condition:   Psoriasis
Interventions:   Drug: Ustekinumab/Methotrexate;   Drug: Ustekinumab/Methotrexate
Sponsor:   Janssen-Cilag International NV
Recruiting - verified February 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Conditions:   Influenza A Virus, H1N1 Subtype;   Influenza B Virus;   Influenza, Human;   Influenza, Seasonal
Intervention:   Drug: zanamivir aqueous solution
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Lymphocytic Leukemia, Chronic
Interventions:   Drug: RO5072759;   Drug: rituximab;   Drug: chlorambucil
Sponsors:   Hoffmann-La Roche;   Genentech
Recruiting - verified February 2010

Condition:   Thyroid Neoplasm
Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
Sponsors:   Bayer;   Onyx Pharmaceuticals
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: protein expression analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Other: questionnaire administration;   Procedure: cognitive assessment
Sponsor:   Medical Research Council
Recruiting - verified February 2010

Condition:   Common Cold
Interventions:   Drug: Aspirin (Acetylsalicylic Acid, Bay E4465);   Drug: Aspirin (Acetylsalicylic Acid, Bay E4465);   Drug: Pseudoephedrine;   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2010

Condition:   Dental Pain
Interventions:   Drug: Diclofenac HPBCD s.c. 75mg/ml;   Drug: Voltarol 75mg/3ml i.m.
Sponsor:   IBSA Institut Biochimique SA
Recruiting - verified February 2010

Condition:   Venous Leg Ulcer
Interventions:   Device: Dermagraft(R);   Device: Profore
Sponsor:   Advanced BioHealing, Inc.
Recruiting - verified February 2010

Condition:   Immune Thrombocytopenic Purpura
Interventions:   Drug: eltrombopag;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Intervention:   Drug: tocilizumab [RoActemra]
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Prostate Cancer
Interventions:   Drug: Ipilimumab;   Drug: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Condition:   Renal Cell Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: interferon alfa-2a
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Conditions:   Acute Lung Injury;   Acute Respiratory Distress Syndrome
Intervention:   Drug: Interferon Beta
Sponsor:   Faron Pharmaceuticals Ltd
Recruiting - verified March 2009

Conditions:   Tuberous Sclerosis;   Subependymal Giant Cell Astrocytoma
Interventions:   Drug: Everolimus (RAD001);   Other: Placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2010

Condition:   Anemia
Interventions:   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Epilepsies, Partial
Intervention:  
Sponsor:   UCB, Inc.
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Intervention:   Drug: tocilizumab [RoActemra]
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Neuroendocrine Tumors
Intervention:  
Sponsor:   Ipsen
Recruiting - verified February 2010

Condition:   Prostatic Neoplasms
Interventions:   Drug: placebo + docetaxel/prednisone;   Drug: dasatinib + docetaxel/prednisone
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Thyroid Cancer
Interventions:   Drug: XL184;   Drug: Placebo
Sponsor:   Exelixis
Recruiting - verified March 2010

Conditions:   Hormone Refractory Prostate Cancer;   Bone Metastases
Interventions:   Drug: Alpharadin (Radium-223);   Drug: Placebo
Sponsor:   Algeta ASA
Recruiting - verified March 2009

Condition:   Prostatic Neoplasms
Interventions:   Drug: Prednisone;   Drug: sunitinib;   Drug: Placebo;   Drug: Prednisone
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Aspergillosis
Interventions:   Drug: voriconazole;   Drug: anidulafungin;   Drug: voriconazole
Sponsors:   Pfizer;   Mycoses Study Group
Recruiting - verified February 2010

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: warfarin;   Drug: apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: capecitabine;   Other: clinical observation;   Procedure: adjuvant therapy
Sponsor:   Southampton University Hospitals NHS Trust
Recruiting - verified March 2008

Condition:   Endocrine Tumors
Interventions:   Drug: lanreotide (Autogel formulation);   Other: Placebo
Sponsor:   Ipsen
Recruiting - verified March 2010

Condition:   HIV Infections
Intervention:   Drug: Tipranavir
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Available - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsor:   European Organization for Research and Treatment of Cancer
Recruiting - verified July 2009